Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study
- Equal contributors
1 Molecular Pathology and Pharmacogenetic Group. Pathology Department, Santa Lucía General University Hospital (HGUSL), 30202, Cartagena, Spain
2 Haematology Department. (HGUSL), 30202, Cartagena, Spain
3 Internal Medicine Department. (HGUSL), 30202, Cartagena, Spain
4 Haematology Department, Morales Meseguer University Hospital (HGUMM), Murcia, Spain
5 Department of Medicine, Centro Regional de Hemodonación, 30003, Murcia, Spain
BMC Cancer 2013, 13:228 doi:10.1186/1471-2407-13-228Published: 7 May 2013
The interplay between genetic susceptibility and carcinogenic exposure is important in the development of haematopoietic malignancies. EPHX1, NQO1 and PON1 are three genes encoding proteins directly involved in the detoxification of potential carcinogens.
We have studied the prevalence of three functional polymorphisms affecting these genes rs1051740 EPHX1, rs1800566 NQO1 and rs662 PON1 in 215 patients with lymphoma and 214 healthy controls.
Genotype frequencies for EPHX and NQO1 polymorphisms did not show any correlation with disease. In contrast, the GG genotype in the PON1 polymorphism was found to be strongly associated with the disease (15.3% vs. 4.7%; OR = 3.7 CI (95%): 1.8-7.7; p < 0.001). According to the pathological diagnosis this association was related to follicular (p = 0.004) and diffuse large B-cell (p = 0.016) lymphomas.
Despite the fact that further confirmation is needed, this study shows that the PON1 GG genotype in rs662 polymorphism could be a risk factor for B-cell lymphomas.